Article
Immunology
Matthew D. Patrick, Ramkumar T. Annamalai
Summary: This study enhances the immunomodulatory potential of mesenchymal stromal cells (MSC) by priming them with IFN gamma and TNF alpha, and develops gelatin-based microgels. These microgels possess adsorption capacity and sustained release effect, showing great potential in immunomodulation.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Zhenbo Tu, Antoine E. Karnoub
Summary: Mesenchymal stem/stromal cells (MSCs) are a heterogeneous population of fibroblastic progenitor cells that reside in multiple tissues around the body and have the ability to differentiate into various connective tissue cells. They play critical regulatory roles in breast tumor development and progression, participating in multiple aspects of the process.
SEMINARS IN CANCER BIOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Madalina Dumitrescu, Ana Maria Vacaru, Violeta Georgeta Trusca, Ioana Madalina Fenyo, Radu Ionita, Anca Violeta Gafencu
Summary: Adenoviral vectors are important for gene delivery into mammalian cells, and in this study, the use of the K2 Transfection System significantly enhanced adenoviral transduction efficiency in MSC derived from different mouse strains. K2TS did not affect the expression of receptors, but rather desensitized the cells to foreign DNA, facilitating virus entry without altering the main characteristics of the MSC.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Editorial Material
Engineering, Biomedical
Michael Schrodt, James A. Ankrum
Summary: Coating mesenchymal stromal cells with a soft gel incorporating specific chemomechanical cues enhances their ability to inhibit aberrant tissue remodelling in fibrotic lungs in mice.
NATURE BIOMEDICAL ENGINEERING
(2022)
Article
Biochemistry & Molecular Biology
Elia Bari, Fulvio Tartara, Fabio Cofano, Giuseppe di Perna, Diego Garbossa, Sara Perteghella, Marzio Sorlini, Delia Mandracchia, Lorella Giovannelli, Paolo Gaetani, Maria Luisa Torre, Lorena Segale
Summary: The study found that the mesenchymal stem cell-secretome Lyosecretome has a significant improvement effect on the osteoinductive and osteoconductive properties of titanium cages, leading to increased mineralized matrix when used during culturing.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Immunology
Alasdair G. Kay, James M. Fox, James P. Hewitson, Andrew P. Stone, Sophie Robertson, Sally James, Xiao-nong Wang, Elizabeth Kapasa, Xuebin B. Yang, Paul G. Genever
Summary: The heterogeneity of bone marrow mesenchymal stromal cells (MSCs) poses challenges for their clinical development. A subtype of MSCs characterized by CD317 expression has been identified, and they show a constitutive interferon signature linked to human disease. CD317(pos) MSCs induce tissue damage in a skin inflammation model, while CD317(neg) MSCs have no effect. CD317(neg) MSCs can suppress the proliferation of activated human T cells, while CD317(pos) MSCs increase the polarization towards pro-inflammatory Th1 cells. CD317(neg) and CD317(pos) MSCs can suppress leukocyte recruitment, but only CD317(neg) MSCs suppress macrophage numbers.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Bjarke Follin, Cecilie Hoeeg, Lisbeth D. Hojgaard, Morten Juhl, Kaya B. Lund, Kristina B. Dossing, Simon Bentsen, Ingrid Hunter, Carsten H. Nielsen, Rasmus S. Ripa, Jens Kastrup, Annette Ekblond, Andreas Kjaer
Summary: In a rat model of chronic ischemic cardiomyopathy, treatment with ASC initiated an immune response involving monocytes/macrophages and T-cells, inducing a gene expression pattern associated with angiogenesis and monocyte/macrophage differentiation.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Cell & Tissue Engineering
Laurent Renesme, Maria Pierro, Kelly D. Cobey, Rhea Mital, Kennedy Nangle, Risa Shorr, Manoj M. Lalu, Bernard Thebaud
Summary: This study conducted a scoping review on original MSC preclinical and clinical studies to investigate the current definitions and characterizations of MSCs. The results showed inconsistent descriptions of MSC products and incomplete reporting of MSC characteristics and culture conditions. Only a small percentage of articles referred to the minimal criteria provided by ISCT. Clinical studies were inconsistent in reporting relevant information on MSC characterization and cell manufacturing processes. These findings suggest the need for further development and implementation of consensus definitions and reporting guidelines for MSCs to improve rigor, reproducibility, and transparency in MSC research.
STEM CELLS TRANSLATIONAL MEDICINE
(2022)
Article
Cell Biology
Rafael Sanchez-Sanchez, Marta Gomez-Ferrer, Ignacio Reinal, Marc Buigues, Estela Villanueva-Badenas, Imelda Ontoria-Oviedo, Amparo Hernandiz, Hernan Gonzalez-King, Esteban Peiro-Molina, Akaitz Dorronsoro, Pilar Sepulveda
Summary: Extracellular vesicles derived from mesenchymal stromal cells (MSCs) and containing miR-4732-3p microRNA show potential for cardioprotection, with miR-4732-3p being regulated by hypoxia and exerting protective actions against ischemic insult.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Review
Cell Biology
Jancy Johnson, Mozhgan Shojaee, James Mitchell Crow, Ramin Khanabdali
Summary: MSCs, as a leading cell source for stem cell therapy, have regenerative and immunomodulatory properties, but face challenges in clinical applications. EVs and EEVs, as potential cell-free alternatives, may overcome these challenges in the clinical application of MSCs.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Review
Biotechnology & Applied Microbiology
Yesuf Siraj, Umberto Galderisi, Nicola Alessio
Summary: Mesenchymal stromal cells (MSCs) are a heterogeneous population of adult stem cells that can differentiate into mesodermal derivatives. MSCs have therapeutic effects due to their secretome, which has anti-inflammatory and regenerative properties. However, when MSCs become senescent, their secretome can acquire pro-inflammatory and pro-aging activities, which should be considered in therapeutic applications.
FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY
(2023)
Review
Cell Biology
David Garcia-Bernal, Mariano Garcia-Arranz, Rosa M. Yanez, Rosario Hervas-Salcedo, Alfonso Cortes, Maria Fernandez-Garcia, Miriam Hernando-Rodriguez, Oscar Quintana-Bustamante, Juan A. Bueren, Damian Garcia-Olmo, Jose M. Moraleda, Jose C. Segovia, Agustin G. Zapata
Summary: MSCs are widely used in advanced therapies for various purposes, mainly related to inflammatory processes. Despite their demonstrated efficacy in preclinical models and early clinical trials, there are still controversies regarding their specific phenotype, delivery methods, and varied cell products. Strategies for bioengineering MSCs are being explored to enhance their properties and functional capabilities.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Review
Cell Biology
Cyril Bouland, Pierre Philippart, Didier Dequanter, Florent Corrillon, Isabelle Loeb, Dominique Bron, Laurence Lagneaux, Nathalie Meuleman
Summary: Bone regeneration is a complex process relying on interactions between osteogenesis and angiogenesis. Tissue engineering provides strategies with regenerative cell sources, growth factors, and mechanical stimulation. Vascularization is crucial for bone formation and function, with studies showing synergy between mesenchymal stromal cells (MSCs) and endothelial progenitor cells (EPCs) in promoting regeneration.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Review
Health Care Sciences & Services
David M. Z. B. Hennes, Anna Rosamilia, Jerome A. Werkmeister, Caroline E. Gargett, Shayanti Mukherjee
Summary: Endometrial mesenchymal stem/progenitor cells (eMSC) show potential for applications in treating chronic and degenerative human diseases, with less invasive extraction methods and improved potency and proliferative capacity. They are particularly useful for pelvic organ prolapse treatment.
JOURNAL OF PERSONALIZED MEDICINE
(2021)
Article
Cell & Tissue Engineering
Seiko Harada, Yo Mabuchi, Jun Kohyama, Daisuke Shimojo, Sadafumi Suzuki, Yoshimi Kawamura, Daisuke Araki, Takashi Suyama, Masunori Kajikawa, Chihiro Akazawa, Hideyuki Okano, Yumi Matsuzaki
Summary: The study compared gene expression profiles of immature hMSCs and less potent MSCs to explore the molecular mechanisms regulating senescence in hMSCs. It was found that FZD5, a transcription factor expressed specifically in immature hMSCs, plays a crucial role in regulating senescence by promoting proliferation and delaying cell cycle arrest. Controlling FZD5 signaling may offer potential to improve hMSC quality for cell-replacement therapies.
Article
Oncology
Christopher D'Angelo, Sailendharan Sudakaran, Fotis Asimakopoulos, Peiman Hematti, Dalia El-Gamal, Nasia Safdar, Natalie Callander
Summary: This study evaluated the gut microbiome and dietary intake in multiple myeloma patients undergoing autologous stem cell transplantation. The research found that a decrease in microbiome diversity after transplantation was associated with impaired treatment response.
LEUKEMIA & LYMPHOMA
(2023)
Review
Oncology
Moazzam Shahzad, Sibgha Gull Chaudhary, Ezza Tariq, Ali Hassan Mushtaq, Iqra Anwar, Nausheen Ahmed, Rajat Bansal, Forat Lutfi, Ramesh Balusu, Haitham Abdelhakim, Abdulraheem Yacoub, Peiman Hematti, Anurag K. Singh, Joseph P. McGuirk, Muhammad Umair Mushtaq
Summary: This study systematically evaluated the primary and secondary endpoints used in acute myeloid leukemia (AML) phase III randomized controlled trials (RCTs) over the past 15 years. The results showed that overall survival (OS), progression-free survival (PFS), event-free survival (EFS), and complete remission (CR) were the most common primary endpoints, while OS, PFS, CR, safety, and EFS were commonly reported secondary endpoints. Furthermore, there was an increasing trend in the use of clinically meaningful and objective endpoint of OS over the last 15 years.
LEUKEMIA & LYMPHOMA
(2023)
Article
Cell & Tissue Engineering
Amanda P. Porter, Bonnie M. Pirlot, Kalyn Dyer, Crystal C. Uwazie, Jimmy Nguyen, Caitlin Turner, Devi Rajan, Peiman Hematti, Raghavan Chinnadurai
Summary: Cell manufacturing facilities need to define the potency of mesenchymal stromal cells (MSCs) as cellular therapeutics. This study investigates the effect of MSCs on B-cell matrix responses and identifies a non-contact dependent mechanism involving the tryptophan metabolic pathway. The results demonstrate that MSCs inhibit B-cell differentiation and antibody secretion, and also inhibit T-cell and B-cell responses when both populations are simultaneously activated.
Article
Cell & Tissue Engineering
Elmira Jalilian, Hamed Massoumi, Bianca Bigit, Sohil Amin, Eitan A. Katz, Victor H. Guaiquil, Khandaker N. Anwar, Peiman Hematti, Mark Rosenblatt, Ali R. Djalilian
Summary: This study compares the differences in neuro-regenerative properties of MSC-derived EVs generated in 2D and 3D culture systems. The findings show that 3D culture system produces EVs with higher concentration, more heterogeneous phenotype, and enhanced ability to promote neurite growth and elongation. This has important implications for the scalable production of MSC-derived EVs and their therapeutic applications.
STEM CELL RESEARCH & THERAPY
(2022)
Article
Biophysics
Muthalagu Ramanathan, Soyoung Kim, Naya He, Min Chen, Peiman Hematti, Muhammad Bilal Abid, Seth J. Rotz, Kirsten M. Williams, Hillard M. Lazarus, Baldeep Wirk, Dwight E. Yin, Christopher G. Kanakry, Miguel-Angel Perales, Roy F. Chemaly, Christopher E. Dandoy, Marcie Riches, Celalettin Ustun
Summary: This study examined the data of patients who underwent the first allogeneic hematopoietic cell transplantation (alloHCT) for AML, ALL, or MDS between 2013 and 2018 in the US. The analysis showed that CDI was associated with inferior overall survival and an increased risk of infection-related mortality.
BONE MARROW TRANSPLANTATION
(2023)
Review
Oncology
Moazzam Shahzad, Ali Hussain, Ezza Tariq, Iqra Anwar, Muhammad S. Faisal, Leena Syed, Alvina Karam, Sibgha Gull Chaudhary, Nausheen Ahmed, Rajat Bansal, Sharad Khurana, Anurag K. Singh, Kenneth P. Byrd, Peiman Hematti, Sunil H. Abhyankar, Joseph P. McGuirk, Muhammad Umair Mushtaq
Summary: We conducted a systematic review and meta-analysis to compare the outcomes of TKI maintenance therapy with or without HSCT in Ph+ ALL in CR1. It was found that TKI alone had a trend towards poor OS, disease-free survival, and higher relapse rate compared to HSCT followed by TKI. The introduction of potent third-generation TKIs and bispecific T-cell engagers has significantly improved outcomes in newly diagnosed patients while sparing the need for HSCT.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2023)
Review
Biochemistry & Molecular Biology
Hamed Massoumi, Sohil Amin, Mohammad Soleimani, Bita Momenaei, Mohammad Javad Ashraf, Victor H. Guaiquil, Peiman Hematti, Mark I. Rosenblatt, Ali R. Djalilian, Elmira Jalilian
Summary: Extracellular vesicles (EVs) are potential candidates for novel therapeutics in various ocular disorders due to their ability to deliver bioactive molecules and promote cell survival and tissue regeneration. EVs derived from different cell types have shown promise in promoting nerve regeneration in ocular diseases. However, the translation of EV-based therapies to the clinic is still facing challenges.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Hematology
C. B. Webb, S. G. Yates, R. Sarode, J. Kim
Summary: Therapeutic plasma exchange (TPE) may be considered as an adjunct treatment for patients with acute complications of sickle cell disease (SCD) that progress to multiple organ dysfunction syndrome (MODS), especially in cases where there is no significant improvement following red cell exchange (RBCx).
Article
Oncology
Jenna L. L. Hansen, Mark B. B. Juckett, Mikayla A. A. Foster, Meredith E. E. Rumble, Keayra E. E. Morris, Peiman Hematti, Erin S. S. Costanzo
Summary: This study comprehensively evaluated physical and psychological function among individuals with cGVHD and investigated the relationships between disease severity and psychological and physical function, as well as patterns of function by disease site. The results showed that patients with cGVHD in the skin and GI tract had the most severe symptoms, including mood disturbance, fatigue, and pain. These findings suggest that patients with more severe cGVHD and those with cGVHD manifesting in specific sites are at risk for poorer psychological and physical outcomes and may benefit from proactive interventions to optimize function.
JOURNAL OF CANCER SURVIVORSHIP
(2023)
Article
Clinical Neurology
Kent J. MacLaughlin, Gregory P. Barton, Rudolf K. Braun, Julia E. MacLaughlin, Jacob J. Lamers, Mathew D. Marcou, Marlowe W. Eldridge
Summary: This study found that hyperbaric air can mobilize stem progenitor cells and modulate cytokines. Hyperbaric air may be a therapeutic treatment, and further investigation is needed to explore its potential as a pharmaceutical/therapy.
FRONTIERS IN NEUROLOGY
(2023)
Article
Multidisciplinary Sciences
Nicholas J. Hess, David P. Turicek, Jeremiah Riendeau, Sean J. McIlwain, Emmanuel Contreras Guzman, Kalyan Nadiminti, Amy Hudson, Natalie S. Callander, Melissa C. Skala, Jenny E. Gumperz, Peiman Hematti, Christian M. Capitini
Summary: An important aspect of allogeneic hematopoietic cell transplantations is finding a way to prevent graft-versus-host disease (GVHD) while still maintaining the graft-versus-leukemia (GVL) activity of donor T cells. In an observational clinical study, a specific type of T cell called CD4+/CD8+ double-positive T cell (DPT) was identified in recipients of allo-HCT, and its presence was found to be predictive of severe GVHD. Further experiments using a transplant model revealed that DPTs develop from antigen-stimulated CD8 T cells and exhibit distinct characteristics from single-positive CD4 and CD8 T cells. These findings highlight the role of DPTs in GVHD pathology.
Article
Biology
Crystal C. C. Uwazie, Tyler U. U. Faircloth, Rhett N. N. Parr, Yenamala U. U. Reddy, Peiman Hematti, Devi Rajan, Raghavan Chinnadurai
Summary: In this study, the researchers investigated the effects of human bone-marrow-derived MSCs on peripheral blood dendritic cell responses. They found that plasmacytoid dendritic cells were not significantly affected by MSCs, but myeloid dendritic cells showed increased maturation. The study also identified the secretory factors associated with MSC-mediated upregulation of myeloid dendritic cell maturation. These findings suggest that circulating dendritic cell subsets may serve as potency biomarkers in MSC therapy.
Article
Hematology
Jihee Choi, John Emmanuel Markantonis, Nicole De Simone, Alecia Nero, Jaehyup Kim, Ravi Sarode
Summary: This retrospective chart review study assessed the safety of maintaining higher HbS targets in SCD patients with a low risk of cerebrovascular accidents (CVA) by reviewing the medical records of patients receiving chronic RBCx with a target of HbS <50% over the past 10-year period. The results showed that there were no stroke or transient ischemic attack (TIA) clearly attributable to changing HbS targets among the 33 study subjects. Conclusion: Liberalizing the HbS target could provide clinical flexibility without increasing the risk of CVA in a selective population.
JOURNAL OF CLINICAL APHERESIS
(2023)
Article
Medicine, Research & Experimental
Andrew Kirvin-Quamme, Meredith E. Rumble, Lisa Cadmus-Bertram, Mark B. Juckett, Paul J. Rathouz, Gwynneth Schell, Natalie S. Callander, Peiman Hematti, Erin S. Costanzo
Summary: This study aims to evaluate a novel behavioral intervention, ReSET, in order to improve insomnia, fatigue, and depression in hematologic cancer patients recovering from HCT. By optimizing rest-activity patterns, these symptoms can be alleviated and patient recovery can be facilitated. A pilot trial will be conducted to assess the feasibility and acceptability of ReSET, with primary outcome measures including patient-reported symptoms, actigraphy, and participant satisfaction measured through semi-structured interviews.
CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS
(2022)
Article
Hematology
Anurag Singh, Christopher E. Dandoy, Min Chen, Soyoung Kim, Carolyn M. Mulroney, Mohamed A. Kharfan-Dabaja, Siddhartha Ganguly, Richard T. Maziarz, Christopher G. Kanakry, Jennifer A. Kanakry, Sagar S. Patel, Joshua A. Hill, Satiro De Oliveir, Randy Taplitz, Peiman Hematti, Hillard M. Lazarus, Muhammad Bilal Abid, Scott R. Goldsmith, Rizwan Romee, Krishna Komanduri, Sherif M. Badawy, Brian D. Friend, Amer Beitinjaneh, Ioannis Politikos, Miguel-Angel Perales, Marcie Riches
Summary: This study evaluates the incidence and outcomes of non-CMV herpesvirus infections in recipients of haploidentical and fully matched transplantations with post-transplantation cyclophosphamide (PTCy). The results indicate a higher risk of NCHV infections in the PTCy groups, particularly in the HaploCy group. The development of NCHV infection is associated with increased treatment-related mortality.
TRANSPLANTATION AND CELLULAR THERAPY
(2022)